Accessibility Menu
Annexon logo

Annexon

(NASDAQ) ANNX

Current Price$5.89
Market Cap$1.06BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2020)-63%
5 Year-72%
1 Year+160%
1 Month+40%
Annexon last closing stock price
MetricPriceDate
Last closeUSD 6.502026-07-15
Annexon stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+9.06%USD 5.962026-07-08
1 month+40.09%USD 4.642026-06-15
3 month+2.69%USD 6.332026-04-16
Year to date+29.48%USD 5.022025-12-31
1 year+160%USD 2.502025-07-15
3 year+76.63%USD 3.682023-07-14
5 year-71.73%USD 22.992021-07-16
Since inception-63.4%USD 17.762020-07-24

Annexon Financials at a Glance

Market Cap

$1.06BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$196.48M

EPS (TTM)

-$1.22

P/E Ratio

-5.35

Dividend

$0.00

Beta (Volatility)

1.14 (Average)

Price

$5.89

Volume

7,710,772

Open

$6.50

Previous Close

$5.89

Daily Range

$5.78 - $6.58

52-Week Range

$2.03 - $7.18

Estimated Earnings Date

Aug 13, 2026

ANNX News

Foolcom-Featured.png

Annexon Narrows Loss in Fiscal Q2

Motley Fool Markets TeamAug 14, 2025
optometrist testing patients vision (1)

Why Shares of Annexon Are Plummeting Thursday

James HalleyMay 25, 2023
A medical professional using a microscope

Why Annexon Biosciences Stock Plummeted 34% Today

Eric VolkmanJan 5, 2022

ANNX: Motley Fool Moneyball Superscore

64

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Annexon

Annexon makes medicines for people with nerve and eye problems. Its drugs stop the body from hurting its own healthy cells. This helps patients move better and save their eyesight.

A Look at the Pipeline

  • Tanruprubart: Single infusion designed to stop nerve damage in Guillain-Barre Syndrome, a rare paralytic disease.
  • Vonaprument: Monthly eye injection aiming to save sight in patients with geographic atrophy, a form of blindness.
  • ANX1502: Experimental oral pill being studied as a treatment for chronic autoimmune conditions.
  • ANX009: Subcutaneous injection developed to reduce inflammation in patients with lupus nephritis.

Major Milestones and Trial Data

  • Filed a Marketing Authorization Application with the European Medicines Agency for tanruprubart in early 2026.
  • Finished enrolling 659 patients for the Phase 3 ARCHER II clinical trial in July 2025.
  • Selected for a Product Development Coordinator Pilot by the European Medicines Agency in July 2025 to assist with regulatory reviews.
  • Maintained an exclusive licensing agreement with Stanford University to develop immune-targeting treatments for neurodegeneration.

How Annexon Stops Nerve Damage

Annexon targets C1q, which is the starting molecule of the body's classical complement pathway in the immune system. This specific focus stops the body's inflammatory cascade without harming other natural defenses used to fight infections.

Performance and Cash Flow Trends

  • Net income was -$48.3 million in 2025, improved 0.7% year-over-year.
  • Operating income reached -$50.3 million in 2025, improved 4.2% year-over-year.
  • Free cash flow hit -$45.9 million in 2025, worsened 27.5% year-over-year.
  • Market capitalization grew to $778.6 million in 2025, up 2.7% from 2024.
  • Total revenue reached $0 for the fiscal year ended December 31, 2025.

Final Word

Annexon has evolved from an early research firm into a late-stage clinical developer of targeted immunotherapies. Its platform approach allows it to address diverse neuroinflammatory diseases of the body, brain, and eye using a single biological target.

AI Generated • May 2, 2026

Industry

Biotechnology

Sector

Health Care

Employees

96

CEO

Douglas Love

Website

www.annexonbio.com

Headquarters

Brisbane, CA 94005, US

ANNX Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-101.19%

Return on Capital

-90.99%

Return on Assets

-74.74%

Earnings Yield

-18.69%

Dividend Yield

0.00%

Payout Ratio

-0.95%

Stock Overview

Market Cap

$1.06BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

163.84M

Volume

7.71M

Avg. Volume

3.35M

Financials (TTM)

Gross Profit

-$1.90M

Operating Income

-$205.06M

EBITDA

-$193.41M

Operating Cash Flow

-$183.10M

Capital Expenditure

-$63.00K

Free Cash Flow

-$183.16M

Cash & ST Invst.

$225.03M

Total Debt

$25.43M

Annexon Performance Analysis

Annexon annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 0N/A
20232023-12-31USD 0N/A
20242024-12-31USD 0N/A
20252025-12-31USD 0N/A
Annexon sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30N/A
Q32025-09-30N/A
Q42025-12-31N/A
Q12026-03-31N/A
Annexon annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -2.60-23.7%
20232023-12-31USD -1.77-31.7%
20242024-12-31USD -1.01-43.3%
20252025-12-31USD -1.3433.7%
Annexon sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-308.1%
Q32025-09-30-8.8%
Q42025-12-3124.3%
Q12026-03-3117.9%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

-$957.00K

N/A

Gross Margin

0.00%

N/A

Market Cap

$1.06BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$11.09M

N/A

Employees

96

N/A

Net Income

-$44.14M

+18.8%

EBITDA

-$43.19M

+19.8%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$225.03M

-14.7%

Total Debt

$25.43M

-10.2%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$22.42M

-12.7%

Short Term Debt

$3.02M

+15.3%

Return on Assets

-74.74%

N/A

Return on Invested Capital

-90.35%

N/A

Free Cash Flow

-$46.80M

+6.6%

Operating Cash Flow

-$46.80M

+6.5%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
LBRXLB Pharmaceuticals Inc Common Stock
$30.59-4.88%
AURAAura Biosciences, Inc.
$6.89-1.71%
DMACDiaMedica Therapeutics Inc.
$7.13-6.68%
DBVTDBV Technologies S.A.
$14.86-5.41%

Trending Stocks

Symbol / CompanyPricePrice Chg
AALAmerican Airlines Group
$15.60-0.00%
ATAIAtaiBeckley
$7.15+0.33%
NOKNokia
$10.38-0.08%
ONDSOndas
$6.65-0.06%

Questions About ANNX

What is the current price of Annexon?

Annexon is trading at $5.89 per share.

What is the 52-week range for Annexon?

Over the past 52 weeks, Annexon has traded between $2.03 and $7.18.

How much debt does Annexon have?

As of the most recent reporting period, Annexon reported total debt of $25.43M.

How much cash does Annexon have on hand?

Annexon reported $175.21M in cash and cash equivalents in its most recent financial results.

What is Annexon’s dividend yield?

Annexon does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services